- Home
- FLNG vs XGN Comparison
FLNG vs XGN Comparison
Compare FLNG & XGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FLNG
- XGN
- Stock Information
- Founded
- FLNG 2006
- XGN 2002
- Country
- FLNG Bermuda
- XGN United States
- Employees
- FLNG N/A
- XGN N/A
- Industry
- FLNG Marine Transportation
- XGN Medical Specialities
- Sector
- FLNG Consumer Discretionary
- XGN Health Care
- Exchange
- FLNG Nasdaq
- XGN Nasdaq
- Market Cap
- FLNG 1.3B
- XGN 138.3M
- IPO Year
- FLNG N/A
- XGN 2019
- Fundamental
- Price
- FLNG $22.57
- XGN $7.07
- Analyst Decision
- FLNG Hold
- XGN Strong Buy
- Analyst Count
- FLNG 1
- XGN 2
- Target Price
- FLNG $23.00
- XGN $7.50
- AVG Volume (30 Days)
- FLNG 448.6K
- XGN 259.6K
- Earning Date
- FLNG 08-13-2025
- XGN 08-04-2025
- Dividend Yield
- FLNG 13.30%
- XGN N/A
- EPS Growth
- FLNG N/A
- XGN N/A
- EPS
- FLNG 1.91
- XGN N/A
- Revenue
- FLNG $354,551,000.00
- XGN $56,724,000.00
- Revenue This Year
- FLNG N/A
- XGN $18.92
- Revenue Next Year
- FLNG $3.64
- XGN $14.78
- P/E Ratio
- FLNG $12.02
- XGN N/A
- Revenue Growth
- FLNG N/A
- XGN 1.78
- 52 Week Low
- FLNG $19.46
- XGN $1.78
- 52 Week High
- FLNG $27.77
- XGN $7.95
- Technical
- Relative Strength Index (RSI)
- FLNG 41.62
- XGN 54.01
- Support Level
- FLNG $22.42
- XGN $6.57
- Resistance Level
- FLNG $22.97
- XGN $7.15
- Average True Range (ATR)
- FLNG 0.51
- XGN 0.33
- MACD
- FLNG -0.03
- XGN -0.04
- Stochastic Oscillator
- FLNG 35.96
- XGN 61.73
About FLNG FLEX LNG Ltd.
Flex LNG Ltd is an LNG shipping company with a fleet of next-generation LNG carriers with large cargo capacity. The fleet consists of thirteen modern LNG ships, ten existing and three under construction for delivery. All LNG carriers are equipped with slow-speed, two-stroke engines MEGI or X-DF propulsion which will provide Charterers with tonnage offering advantages in form of reduced fuel consumption and lowered boil-off rates.
About XGN Exagen Inc.
Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.